Primary Immunodeficiency Therapeutic Market, Global Outlook and Forecast 2023-2028

Report ID: 1857214 | Published Date: Jan 2025 | No. of Page: 63 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Primary Immunodeficiency Therapeutic Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Primary Immunodeficiency Therapeutic Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Primary Immunodeficiency Therapeutic Overall Market Size
    2.1 Global Primary Immunodeficiency Therapeutic Market Size: 2021 VS 2028
    2.2 Global Primary Immunodeficiency Therapeutic Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Primary Immunodeficiency Therapeutic Players in Global Market
    3.2 Top Global Primary Immunodeficiency Therapeutic Companies Ranked by Revenue
    3.3 Global Primary Immunodeficiency Therapeutic Revenue by Companies
    3.4 Top 3 and Top 5 Primary Immunodeficiency Therapeutic Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Primary Immunodeficiency Therapeutic Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Players in Global Market
        3.6.1 List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies
        3.6.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Primary Immunodeficiency Therapeutic Market Size Markets, 2021 & 2028
        4.1.2 Immunoglobulin Replacement Therapy
        4.1.3 Stem Cell or Bone Marrow Transplantation
        4.1.4 Antibiotic Therapy
        4.1.5 Gene Therapy
        4.1.6 Others
    4.2 By Type - Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
        4.2.1 By Type - Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
        4.2.2 By Type - Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
        4.2.3 By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Primary Immunodeficiency Therapeutic Market Size, 2021 & 2028
        5.1.2 Antibody Deficiency
        5.1.3 Cellular Immunodeficiency
        5.1.4 Innate Immune Disorders
        5.1.5 Others
    5.2 By Application - Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
        5.2.1 By Application - Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
        5.2.2 By Application - Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
        5.2.3 By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Primary Immunodeficiency Therapeutic Market Size, 2021 & 2028
    6.2 By Region - Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
        6.2.1 By Region - Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
        6.2.2 By Region - Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
        6.2.3 By Region - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Primary Immunodeficiency Therapeutic Revenue, 2017-2028
        6.3.2 US Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.3.3 Canada Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.3.4 Mexico Primary Immunodeficiency Therapeutic Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Primary Immunodeficiency Therapeutic Revenue, 2017-2028
        6.4.2 Germany Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.4.3 France Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.4.4 U.K. Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.4.5 Italy Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.4.6 Russia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.4.7 Nordic Countries Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.4.8 Benelux Primary Immunodeficiency Therapeutic Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Primary Immunodeficiency Therapeutic Revenue, 2017-2028
        6.5.2 China Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.5.3 Japan Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.5.4 South Korea Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.5.5 Southeast Asia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.5.6 India Primary Immunodeficiency Therapeutic Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Primary Immunodeficiency Therapeutic Revenue, 2017-2028
        6.6.2 Brazil Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.6.3 Argentina Primary Immunodeficiency Therapeutic Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, 2017-2028
        6.7.2 Turkey Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.7.3 Israel Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.7.4 Saudi Arabia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
        6.7.5 UAE Primary Immunodeficiency Therapeutic Market Size, 2017-2028
7 Players Profiles
    7.1 Baxter International
        7.1.1 Baxter International Corporate Summary
        7.1.2 Baxter International Business Overview
        7.1.3 Baxter International Primary Immunodeficiency Therapeutic Major Product Offerings
        7.1.4 Baxter International Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.1.5 Baxter International Key News
    7.2 Takeda Pharmaceutical
        7.2.1 Takeda Pharmaceutical Corporate Summary
        7.2.2 Takeda Pharmaceutical Business Overview
        7.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Major Product Offerings
        7.2.4 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.2.5 Takeda Pharmaceutical Key News
    7.3 CSL Limited
        7.3.1 CSL Limited Corporate Summary
        7.3.2 CSL Limited Business Overview
        7.3.3 CSL Limited Primary Immunodeficiency Therapeutic Major Product Offerings
        7.3.4 CSL Limited Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.3.5 CSL Limited Key News
    7.4 Octapharma
        7.4.1 Octapharma Corporate Summary
        7.4.2 Octapharma Business Overview
        7.4.3 Octapharma Primary Immunodeficiency Therapeutic Major Product Offerings
        7.4.4 Octapharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.4.5 Octapharma Key News
    7.5 Kedrion Biopharma
        7.5.1 Kedrion Biopharma Corporate Summary
        7.5.2 Kedrion Biopharma Business Overview
        7.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Major Product Offerings
        7.5.4 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.5.5 Kedrion Biopharma Key News
    7.6 Bio Products Laboratory
        7.6.1 Bio Products Laboratory Corporate Summary
        7.6.2 Bio Products Laboratory Business Overview
        7.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Major Product Offerings
        7.6.4 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.6.5 Bio Products Laboratory Key News
    7.7 LFB group
        7.7.1 LFB group Corporate Summary
        7.7.2 LFB group Business Overview
        7.7.3 LFB group Primary Immunodeficiency Therapeutic Major Product Offerings
        7.7.4 LFB group Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.7.5 LFB group Key News
    7.8 Grifols
        7.8.1 Grifols Corporate Summary
        7.8.2 Grifols Business Overview
        7.8.3 Grifols Primary Immunodeficiency Therapeutic Major Product Offerings
        7.8.4 Grifols Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.8.5 Grifols Key News
    7.9 Lupin Pharmaceuticals
        7.9.1 Lupin Pharmaceuticals Corporate Summary
        7.9.2 Lupin Pharmaceuticals Business Overview
        7.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Major Product Offerings
        7.9.4 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
        7.9.5 Lupin Pharmaceuticals Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Primary Immunodeficiency Therapeutic Market Opportunities & Trends in Global Market
    Table 2. Primary Immunodeficiency Therapeutic Market Drivers in Global Market
    Table 3. Primary Immunodeficiency Therapeutic Market Restraints in Global Market
    Table 4. Key Players of Primary Immunodeficiency Therapeutic in Global Market
    Table 5. Top Primary Immunodeficiency Therapeutic Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Primary Immunodeficiency Therapeutic Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Primary Immunodeficiency Therapeutic Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Primary Immunodeficiency Therapeutic Product Type
    Table 9. List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
    Table 30. Baxter International Corporate Summary
    Table 31. Baxter International Primary Immunodeficiency Therapeutic Product Offerings
    Table 32. Baxter International Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 33. Takeda Pharmaceutical Corporate Summary
    Table 34. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product Offerings
    Table 35. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 36. CSL Limited Corporate Summary
    Table 37. CSL Limited Primary Immunodeficiency Therapeutic Product Offerings
    Table 38. CSL Limited Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 39. Octapharma Corporate Summary
    Table 40. Octapharma Primary Immunodeficiency Therapeutic Product Offerings
    Table 41. Octapharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 42. Kedrion Biopharma Corporate Summary
    Table 43. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product Offerings
    Table 44. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 45. Bio Products Laboratory Corporate Summary
    Table 46. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product Offerings
    Table 47. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 48. LFB group Corporate Summary
    Table 49. LFB group Primary Immunodeficiency Therapeutic Product Offerings
    Table 50. LFB group Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 51. Grifols Corporate Summary
    Table 52. Grifols Primary Immunodeficiency Therapeutic Product Offerings
    Table 53. Grifols Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
    Table 54. Lupin Pharmaceuticals Corporate Summary
    Table 55. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product Offerings
    Table 56. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Primary Immunodeficiency Therapeutic Segment by Type in 2021
    Figure 2. Primary Immunodeficiency Therapeutic Segment by Application in 2021
    Figure 3. Global Primary Immunodeficiency Therapeutic Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Primary Immunodeficiency Therapeutic Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Primary Immunodeficiency Therapeutic Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2021
    Figure 8. By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 12. US Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 16. Germany Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 17. France Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 24. China Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 28. India Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 30. Brazil Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
    Figure 33. Turkey Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
    Figure 37. Baxter International Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. CSL Limited Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Octapharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. LFB group Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Grifols Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
Primary Immunodeficiency Therapeutic Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Primary Immunodeficiency Therapeutic Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Primary Immunodeficiency Therapeutic Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports